Guardant Health CCO vests 11,213 RSUs in Form 4

Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity.

Rhea-AI Filing Summary

Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity. On April 1, 2026, multiple installments of his restricted stock unit awards vested, resulting in the acquisition of 11,213 shares of Common Stock at an exercise price of $0.00 per share.

To cover tax obligations tied to this vesting, 4,750 shares were withheld by Guardant Health at a price of $91.15 per share, as noted in the footnotes. After these transactions, Freeman directly owned 60,034 shares of Guardant Health common stock. The RSU awards were originally granted between November 7, 2022 and March 12, 2025 and vest over three- to four-year periods in quarterly installments.

Insider Trade Summary

11,213 shares exercised/converted

Exercise 9 txns

Insider Freeman Chris

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,929	$0.00	$0.00
Exercise	Restricted Stock Units	1,667	$0.00	$0.00
Exercise	Restricted Stock Units	2,526	$0.00	$0.00
Exercise	Restricted Stock Units	5,091	$0.00	$0.00
Exercise	Common Stock	1,929	$0.00	$0.00
Exercise	Common Stock	1,667	$0.00	$0.00
Exercise	Common Stock	2,526	$0.00	$0.00
Exercise	Common Stock	5,091	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,750	$91.15	$433K

Holdings After Transaction: Restricted Stock Units — 32,689 contracts (Direct); Common Stock — 60,034 shares (Direct)

Footnotes (6)

1. F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. F2. This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.
3. F3. Not applicable for Restricted Stock Units.
4. F4. This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
5. F5. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
6. F6. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Key Figures

RSU shares vested: 11,213 shares Shares withheld for taxes: 4,750 shares Tax withholding share price: $91.15 per share +3 more

6 metrics

RSU shares vested 11,213 shares Restricted Stock Units converted to Common Stock on April 1, 2026

Shares withheld for taxes 4,750 shares Retained by Guardant Health to satisfy tax obligations on vesting

Tax withholding share price $91.15 per share Valuation used for 4,750 shares withheld

Shares owned after transactions 60,034 shares Guardant Health common stock directly owned by Chris Freeman after Form 4 events

Derivative exercises 11,213 shares Exercise/conversion of Restricted Stock Units (code M, exerciseCount 4)

Tax withholding transactions 1 transaction Code F disposition for payment of tax liability, 4,750 shares

Key Terms

Restricted Stock Units, tax withholding obligations, vesting, exercise or conversion of derivative security, +1 more

5 terms

Restricted Stock Units financial

"This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units."

vesting financial

"25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Payment of exercise price or tax liability by delivering securities financial

"transaction_code_description: Payment of exercise price or tax liability by delivering securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Guardant Health (GH) Chief Commercial Officer report in this Form 4?

Chris Freeman reported routine equity compensation activity. Several restricted stock unit awards vested into 11,213 shares of Guardant Health common stock, with part of the resulting shares used to satisfy tax withholding obligations.

How many Guardant Health shares did Chris Freeman acquire through RSU vesting?

He acquired 11,213 shares of Guardant Health common stock through the vesting and conversion of multiple restricted stock unit awards, all recorded at an exercise or conversion price of $0.00 per share according to the Form 4 data provided.

How many Guardant Health shares were withheld for taxes in Chris Freeman’s Form 4?

Guardant Health retained 4,750 shares to meet Chris Freeman’s tax withholding obligations related to the RSU vesting. The shares were valued at $91.15 per share, and the footnote states the amount did not exceed the tax liability.

What are Chris Freeman’s Guardant Health holdings after these transactions?

After the RSU vesting and related tax withholding, Chris Freeman directly owned 60,034 shares of Guardant Health common stock. This figure reflects his updated direct holdings as of the transaction date reported in the Form 4.

Over what period do Chris Freeman’s Guardant Health RSU awards vest?

The RSU awards vest over three- to four-year schedules. Footnotes describe grants dated November 7, 2022, December 13, 2023, November 8, 2024, and March 12, 2025, with initial vesting on specific dates and remaining shares vesting in equal quarterly installments.

Was the 4,750-share disposition in Guardant Health stock an open-market sale?

No, the 4,750-share disposition was for tax withholding. The company retained these shares to satisfy Chris Freeman’s tax obligations arising from RSU vesting, and the footnote clarifies the retained amount did not exceed the tax liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 05:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freeman Chris

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		1,929	A	$0	55,500	D
Common Stock	04/01/2026		M		1,667	A	$0	57,167	D
Common Stock	04/01/2026		M		2,526	A	$0	59,693	D
Common Stock	04/01/2026		M		5,091	A	$0	64,784	D
Common Stock	04/01/2026		F		4,750(1)	D	$91.15	60,034	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	04/01/2026		M			1,929	(2)	(3)	Common Stock	1,929	$0	3,857	D
Restricted Stock Units	$0	04/01/2026		M			1,667	(4)	(3)	Common Stock	1,667	$0	3,335	D
Restricted Stock Units	$0	04/01/2026		M			2,526	(5)	(3)	Common Stock	2,526	$0	15,158	D
Restricted Stock Units	$0	04/01/2026		M			5,091	(6)	(3)	Common Stock	5,091	$0	10,339	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

5. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

6. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)